Gao Linying, Cui Xufeng, Mo Xinyuan, Men Zhaoyue, Xu Xiuyang, Yao Tian, Wang Jianmin, Liu Hongting, Guo Hongping, Chai Guowei, Liu Liming, Wang Fuzhen, Liang Xiaofeng, Wang Suping, Feng Yongliang
School of Public Health, Shanxi Medical University, Taiyuan City, Shanxi Province, China.
Key Laboratory of Coal Environmental Pathogenicity and Prevention (Shanxi Medical University), Ministry of Education, Taiyuan City, Shanxi Province, China.
China CDC Wkly. 2024 Dec 13;6(50):1331-1336. doi: 10.46234/ccdcw2024.264.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
WHAT IS ADDED BY THIS REPORT?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.
作为乙肝病毒（HBV）感染的高危人群之一，慢性肾脏病（CKD）患者需要快速有效地产生乙肝表面抗体（抗-HBs）。
乙肝疫苗短疗程、高剂量方案能迅速诱导出与常规方案相当的免疫反应，血清转化率达88.5%，高反应率达64.1%，抗-HBs几何平均浓度为824.1 mIU/mL。
短疗程、高剂量方案是CKD患者有效的快速免疫策略，尤其是在免疫抑制治疗前给药时。本研究为优化CKD人群的免疫方案提供了有力证据。
